Form 15-12B MyoKardia, Inc.
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-37609
|
MYOKARDIA, INC.
|
(Exact name of registrant as specified in its charter)
1000 Sierra Point Parkway
Brisbane, CA 94005
(650) 741-0900
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1)
|
☒
|
|
|
Rule 12g-4(a)(2)
|
☐
|
|
|
Rule 12h-3(b)(1)(i)
|
☒
|
|
|
Rule 12h-3(b)(1)(ii)
|
☐
|
|
|
Rule 15d-6
|
☐
|
|
|
Rule 15d-22(b)
|
☐
|
Approximate number of holders of record as of the certification or notice date: one (1).
Pursuant to the requirements of the Securities Exchange Act of 1934, MyoKardia, Inc. has caused this certification/notice to be signed on
its behalf by the undersigned duly authorized person.
|
Date: November 27, 2020
|
By:
|
/s/ Katherine R. Kelly
|
|
Name: Katherine R. Kelly
Title: Vice President and Secretary
|
||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Black Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board
- Report on Financial Results for the Year Ended December 31, 2023
- Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
